{"DataElement":{"publicId":"12943973","version":"1","preferredName":"Prostate Carcinoma PSMA-targeting Agent-Technetium Tc99m EC0652 PET Scan Category","preferredDefinition":"Based on PSMA-targeting Agent-Technetium Tc99m EC0652 PET scan, the clinical observation of the extent of the distant metastasis for prostate carcinoma based on information obtained from the date of cancer diagnosis until the start of definitive treatment, or within four months (whichever is shorter).","longName":"PC_TC99M_M_CAT","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"12939984","version":"1","preferredName":"Prostate Carcinoma PSMA-targeting Agent-Technetium Tc99m EC0652 Positron Emission Tomography M Category","preferredDefinition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease._A radioconjugate composed of 2-[3-(1, 3-dicarboxy propyl)-ureido] pentanedioic acid (DUPA), a prostate-specific membrane antigen (PSMA)-targeting ligand, linked to the radioisotope technetium Tc 99m (Tc99m), that can potentially be used as a radioimaging agent for PSMA-overexpressing tumor cells. Upon administration, the PSMA-targeting moiety of EC0652 targets and binds to PSMA-expressing tumors. Upon uptake and single-photon emission computed tomography (SPECT) imaging, PSMA-expressing tumors can be visualized and identified. In turn, PSMA-overexpression can be used to evaluate both the efficacy of and response to certain PSMA-targeting cytotoxic agents. PSMA, a tumor-associated antigen (TAA), is overexpressed by most prostate cancers._A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.:One criteria of the TNM staging system. M refers to the presence of metastasis.","longName":"12939971v1.00:2678077v1.00","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"12939971","version":"1","preferredName":"Prostate Carcinoma PSMA-targeting Agent-Technetium Tc99m EC0652 Positron Emission Tomography","preferredDefinition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease._A radioconjugate composed of 2-[3-(1, 3-dicarboxy propyl)-ureido] pentanedioic acid (DUPA), a prostate-specific membrane antigen (PSMA)-targeting ligand, linked to the radioisotope technetium Tc 99m (Tc99m), that can potentially be used as a radioimaging agent for PSMA-overexpressing tumor cells. Upon administration, the PSMA-targeting moiety of EC0652 targets and binds to PSMA-expressing tumors. Upon uptake and single-photon emission computed tomography (SPECT) imaging, PSMA-expressing tumors can be visualized and identified. In turn, PSMA-overexpression can be used to evaluate both the efficacy of and response to certain PSMA-targeting cytotoxic agents. PSMA, a tumor-associated antigen (TAA), is overexpressed by most prostate cancers._A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.","longName":"C4863:C136776:C17007","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Carcinoma","conceptCode":"C4863","definition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"PSMA-targeting Agent-Technetium Tc99m EC0652","conceptCode":"C136776","definition":"A radioconjugate composed of 2-[3-(1, 3-dicarboxy propyl)-ureido] pentanedioic acid (DUPA), a prostate-specific membrane antigen (PSMA)-targeting ligand, linked to the radioisotope technetium Tc 99m (Tc99m), that can potentially be used as a radioimaging agent for PSMA-overexpressing tumor cells. Upon administration, the PSMA-targeting moiety of EC0652 targets and binds to PSMA-expressing tumors. Upon uptake and single-photon emission computed tomography (SPECT) imaging, PSMA-expressing tumors can be visualized and identified. In turn, PSMA-overexpression can be used to evaluate both the efficacy of and response to certain PSMA-targeting cytotoxic agents. PSMA, a tumor-associated antigen (TAA), is overexpressed by most prostate cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Positron Emission Tomography","conceptCode":"C17007","definition":"A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5CF8E94-9AED-52F0-E053-731AD00A4FB7","latestVersionIndicator":"Yes","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2678077","version":"1","preferredName":"M Stage","preferredDefinition":"One criteria of the TNM staging system.  M refers to the presence of metastasis.","longName":"C25727","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"M Category","conceptCode":"C25727","definition":"One criteria of the TNM staging system. M refers to the presence of metastasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3978B83D-5D9A-3E76-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-06","endDate":null,"createdBy":"UMLLOADER_COCANUT","dateCreated":"2007-09-06","modifiedBy":"ONEDATA","dateModified":"2007-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435021","version":"1","preferredName":"Diagnostic or Prognostic Factor","preferredDefinition":"Top level term which includes Biological Markers, Risk Factors, and Prognostic Factors.","longName":"C20047","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741C99A-9B70-231B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5CF959C-E2C3-53C0-E053-731AD00A8B25","latestVersionIndicator":"Yes","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"KUMMEROA","dateModified":"2023-03-03","changeDescription":null,"administrativeNotes":"2023.3.3 Released per CCR review. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"12939850","version":"1","preferredName":"Prostate Carcinoma 99mTc-based PSMA Imaging and Surgery Agent M Category","preferredDefinition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease._A diagnostic radioconjugate composed of a prostate-specific membrane antigen (PSMA)-targeting ligand that is linked, via the bifunctional, macrocyclic chelating agent 1,4,7,10-tetraazacyclododecane-1-(glutamic acid)-4,7,10-triacetic acid (DOTAGA; DOTA-GA), to the radioisotope technetium Tc 99m (Tc99m), that can potentially be used as a radioimaging agent for radio-guided surgery upon single-photon emission computed tomography (SPECT)/computed tomography (CT) for PSMA-overexpressing tumor cells. Upon administration, 99mTc-based PSMA-imaging and surgery (I&S agent targets and binds to PSMA on PSMA-expressing tumor cells. Upon SPECT/CT imaging, PSMA-expressing tumors can be visualized and identified. PSMA, a tumor-associated antigen (TAA), is overexpressed by most prostate cancers._One criteria of the TNM staging system. M refers to the presence of metastasis._A grouping of items based on some commonality or by user defined characteristics.","longName":"PC_TC99M_M_CAT","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"45","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other","valueDescription":null,"ValueMeaning":{"publicId":"6431768","version":"1","preferredName":"Other","longName":"6431768v1.00","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"762A692A-EEF7-29A1-E053-F662850A9EA9","latestVersionIndicator":"Yes","beginDate":"2018-09-18","endDate":null,"createdBy":"WINCHC","dateCreated":"2018-09-18","modifiedBy":"GDEEN","dateModified":"2024-01-22","changeDescription":null,"administrativeNotes":"2023.2.1 Alt VM added per ticket request CADSR0001995. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F5D03394-117B-7618-E053-731AD00A59B8","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","deletedIndicator":"No"},{"value":"M0","valueDescription":null,"ValueMeaning":{"publicId":"3201564","version":"1","preferredName":"M0 Stage Finding","longName":"3201564","preferredDefinition":"A distant metastasis TNM finding indicating that there is no evidence of distant metastasis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"M0 TNM Finding","conceptCode":"C48699","definition":"A distant metastasis TNM finding indicating that there is no evidence of distant metastasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9E24E347-9E82-3835-E040-BB89AD4379CD","latestVersionIndicator":"Yes","beginDate":"2011-03-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-03-10","modifiedBy":"GDEEN","dateModified":"2023-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F5D03F25-56FA-77ED-E053-731AD00A6871","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","deletedIndicator":"No"},{"value":"M1b","valueDescription":null,"ValueMeaning":{"publicId":"3201567","version":"1","preferredName":"M1b Stage Finding","longName":"3201567","preferredDefinition":"A TNM finding indicating the spread of cancer to distant anatomic sites.  The definition of M1b TNM finding depends on the specific type of cancer that it refers to; for example, for colorectal cancer it refers to metastases in more than one organ/site or the peritoneum; for prostate cancer it refers to metastasis to bone(s); for bone cancer it refers to metastasis to distant sites other than lung.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"M1b TNM Finding","conceptCode":"C48702","definition":"A TNM finding indicating the spread of cancer to distant anatomic sites.  The definition of M1b TNM finding depends on the specific type of cancer that it refers to; for example, for colorectal cancer it refers to metastases in more than one organ/site or the peritoneum; for prostate cancer it refers to metastasis to bone(s); for bone cancer it refers to metastasis to distant sites other than lung.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9E24E347-9EEF-3835-E040-BB89AD4379CD","latestVersionIndicator":"Yes","beginDate":"2011-03-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-03-10","modifiedBy":"GDEEN","dateModified":"2023-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F5D03F25-56FB-77ED-E053-731AD00A6871","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"12939849","version":"1","preferredName":"Prostate Carcinoma 99mTc-based PSMA Imaging and Surgery Agent M Category Category","preferredDefinition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease._A diagnostic radioconjugate composed of a prostate-specific membrane antigen (PSMA)-targeting ligand that is linked, via the bifunctional, macrocyclic chelating agent 1,4,7,10-tetraazacyclododecane-1-(glutamic acid)-4,7,10-triacetic acid (DOTAGA; DOTA-GA), to the radioisotope technetium Tc 99m (Tc99m), that can potentially be used as a radioimaging agent for radio-guided surgery upon single-photon emission computed tomography (SPECT)/computed tomography (CT) for PSMA-overexpressing tumor cells. Upon administration, 99mTc-based PSMA-imaging and surgery (I&S agent targets and binds to PSMA on PSMA-expressing tumor cells. Upon SPECT/CT imaging, PSMA-expressing tumors can be visualized and identified. PSMA, a tumor-associated antigen (TAA), is overexpressed by most prostate cancers._One criteria of the TNM staging system. M refers to the presence of metastasis._A grouping of items based on some commonality or by user defined characteristics.","longName":"12939849v1.00","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Carcinoma","conceptCode":"C4863","definition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"99mTc-based PSMA Imaging and Surgery Agent","conceptCode":"C178154","definition":"A diagnostic radioconjugate composed of a prostate-specific membrane antigen (PSMA)-targeting ligand that is linked, via the bifunctional, macrocyclic chelating agent 1,4,7,10-tetraazacyclododecane-1-(glutamic acid)-4,7,10-triacetic acid (DOTAGA; DOTA-GA), to the radioisotope technetium Tc 99m (Tc99m), that can potentially be used as a radioimaging agent for radio-guided surgery upon single-photon emission computed tomography (SPECT)/computed tomography (CT) for PSMA-overexpressing tumor cells. Upon administration, 99mTc-based PSMA-imaging and surgery (I&S agent targets and binds to PSMA on PSMA-expressing tumor cells. Upon SPECT/CT imaging, PSMA-expressing tumors can be visualized and identified. PSMA, a tumor-associated antigen (TAA), is overexpressed by most prostate cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"M Category","conceptCode":"C25727","definition":"One criteria of the TNM staging system. M refers to the presence of metastasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5C9F7DC-ACE4-6510-E053-731AD00A15B5","latestVersionIndicator":"Yes","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5C9F7DC-ACEB-6510-E053-731AD00A15B5","latestVersionIndicator":"Yes","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"KUMMEROA","dateModified":"2023-03-03","changeDescription":null,"administrativeNotes":"2023.3.3 Released per CCR review. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Tc99m (M-stage)","type":"Preferred Question Text","description":"Tc99m (M-stage)","url":null,"context":"CCR"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5D11947-7F4E-0A77-E053-731AD00A68A3","latestVersionIndicator":"Yes","beginDate":"2023-03-01","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-03-01","modifiedBy":"KUMMEROA","dateModified":"2023-03-03","changeDescription":null,"administrativeNotes":"2023.3.3 Released per CCR review. ak","unresolvedIssues":null,"deletedIndicator":"No"}}